

- **Name:** Carlos L. Arteaga
 - **Current Position & Affiliation:** UT Southwestern Harold C. Simmons Cancer Center 5323 Harry Hynes Blvd
 - **Country:** USA
-

• **Educational Background:**

1981(MD.) Facultad de Ciencias Médicas, Universidad de Guayaquil, Ecuador

• **Professional Experience:**

Sept. 2017 – Director, Harold C. Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs, UT Southwestern Medical Center

Feb. 2024 – Annette Simmons Distinguished University Chair in Breast Cancer Research

Sept. 2017 – Professor of Medicine, UT Southwestern Medical Center

Sept. 2017 – Feb. 2024 The Lisa K. Simmons Distinguished Chair in Comprehensive Oncology

Mar. 2013 – Aug. 2017 Director, Center for Cancer Targeted Therapies, Vanderbilt-Ingram Cancer Center (VICC)

Sept. 2010 – Aug. 2017 Associate Director for Translational/Clinical Research VICC

July 2010 – Oct 2011 Interim Director, Division of Hematology-Oncology, Vanderbilt University Medical Center

Dec. 1998 – Aug. 2017 Professor of Medicine and Cancer Biology, Vanderbilt

July 2009 – Aug. 2017 Donna S. Hall Chair in Breast Cancer Research

Jan 1996 – Aug. 2017 Director, VICC Breast Cancer Program

July 1995 - Sept 2000 Clinical Investigator, Department of Research & Development, VA Medical Center, Nashville, TN

Mar 1994 - Feb 1998 Associate Professor (with tenure) of Medicine and Cell Biology, Vanderbilt University

Apr 1990 - Mar 1994 Assistant Professor of Cell Biology, Vanderbilt University

Jan 1991 - Dec 1994 Research Associate, VA Medical Center, Nashville, TN

Aug 1989 - Dec 1990 Associate Investigator, VA Medical Center, Nashville, TN

Aug 1989 - Mar 1994 Assistant Professor of Medicine (Medical Oncology), Vanderbilt University

Jan 1988 - Jul 1989 Associate Investigator, VA Medical Center, San Antonio, TX

1987-1989 Instructor in Medicine, University of Texas Health Science Center, San Antonio, TX

• **Professional Organizations:**

Association of American Physicians (inducted 2005)

American Society of Clinical Investigation (inducted 1998)

American Society of Clinical Oncology

American Association for Cancer Research

American Society of Clinical Oncology

• Main Scientific Publications:

1. Gien LT, Song Z, Poklepovic A, Collison EA, Zwiebel JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Tricoli JV, Conley BA, **Arteaga CL**, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Sunitinib in Tumors with c-KIT mutations: Results from the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V. *JCO Precis. Oncol.* 2024 Dec;8:e2400514. doi: 10.1200/PO-24-00514. Epub 2024 Dec 12. PMID: 39666929 PMCID: PMC11643086
2. Gettinger S, Song Z, Reckamp K, Mitchell EP, Wright JJ, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Kong X-T, Tricoli JV, Conley BA, **Arteaga CL**, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A. *JCO Precis. Oncol.* 2024 Jul;8:e2300725. doi: 10.1200/PO.23.00725. PMID: 38986051
3. Zauderer MG, Jegede O, Jackman DM, Mitchell EP, Zweibel JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Takebe N, Huang R, Carrillo JA, Brenner AJ, Tricoli JC, Conley BA, **Arteaga CL**, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase 2 Study of Defactinib (VS6063) in Patients with Tumors with NF2 Loss: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol-U. *JCO Precis. Oncol.* 2024 Dec;8:e2400327. doi: 10.1200/PO.24.00327. Epub 2024 Dec 18. PMID: 39693587
4. O'hara MH, Dickson MA, Jegede O, DeMichele AM, Mitchell EP, Wright JJ, Arnaldez FI, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Onitilo A, Tricoli JV, Conley BA, **Arteaga CL**, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase 2 Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1C. *Clin. Cancer Res.* 2025 Jan 6;31(1):56-64. doi: 10.1158/1078-0432.CCR-24-0036. PMID: 39437014 PMCID: PMC11721435
5. Gouda M, Wei Z, Rodon J, Davies M, Janku F, Mitchell EP, Wright JJ, Doyle L, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Liu R, Bota DA, Swiecicki PL, Buchschacher GL, Tricoli JV, Conley BA, **Arteaga CL**, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Copanlisib in patients with PTEN loss: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H. *JCO Precis. Oncol.* 2025 Feb;9:e2400451. doi: 10.1200/PO-24-00451. Epub 2025 Feb 6. PMID: 39913886
6. González-Ericsson PI, Unni N, Jhaveri K, Stringer Reasor E, Liu Q, Wang Y, Sánchez V, Garcia G, Sanders ME, Lehmann BD, Balko JM, Park B, Rexer BN, Mayer IA, **Arteaga CL**. Phase Ib trial of Fulvestrant, Palbociclib and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2– Metastatic Breast Cancer. *Clin. Cancer Res. Accepted 2025*
7. Uemoto Y, Lin C-C, Wang B, Ye D, Fang YV, Bikorimana E, Napolitano F, Chica-Parrado MR, Mendiratta S, Chen C, Hanker AB, **Arteaga CL**. Selective degradation of FGFR1/2 overcomes antiestrogen resistance in estrogen receptor-positive breast cancer with FGFR pathway alterations. *Cancer Lett. Accepted 2025*
8. Lin C-C, Chica-Parrado MR, Unni N, Jaeger E, Fang YV, Guo L, Napolitano F, Luna P, Harris M, Chao C, Xu L, **Arteaga CL***, Hanker AB*. ESR1 Y537S and D538G mutations drive resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer. *Clin. Cancer Res. Accepted 2025* * co-corresponding